Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Increase in Short Interest

Aligos Therapeutics, Inc. (NASDAQ:ALGS) saw a significant growth in short interest in January. As of January 15th, there was short interest totalling 597,300 shares, a growth of 30.7% from the December 31st total of 457,100 shares. Based on an average trading volume of 421,900 shares, the short-interest ratio is currently 1.4 days. Approximately 22.4% of the company’s stock are short sold.

Aligos Therapeutics Trading Up 1.4 %

Aligos Therapeutics stock opened at $24.27 on Thursday. Aligos Therapeutics has a 52 week low of $6.76 and a 52 week high of $46.80. The stock has a market cap of $87.13 million, a P/E ratio of -1.83 and a beta of 2.50. The stock has a 50 day moving average of $32.47 and a 200-day moving average of $19.04.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($3.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.15) by ($0.92). The company had revenue of $1.27 million during the quarter, compared to analyst estimates of $1.00 million. Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. During the same period in the prior year, the company earned ($10.25) earnings per share. As a group, equities analysts predict that Aligos Therapeutics will post -10.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aligos Therapeutics

Large investors have recently modified their holdings of the stock. AlphaMark Advisors LLC raised its stake in Aligos Therapeutics by 1,000.0% during the fourth quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company’s stock valued at $44,000 after buying an additional 1,000 shares in the last quarter. Golden State Wealth Management LLC bought a new stake in shares of Aligos Therapeutics in the 4th quarter valued at approximately $107,000. Finally, Drive Wealth Management LLC bought a new stake in shares of Aligos Therapeutics in the 4th quarter valued at approximately $916,000. Institutional investors own 60.43% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $75.00 price target on shares of Aligos Therapeutics in a research note on Thursday, November 7th.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).